OXiGENE Inc. (NASDAQ:MATN) posted its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03.

OXiGENE (NASDAQ:MATN) opened at 0.4921 on Wednesday. OXiGENE has a 12-month low of $0.45 and a 12-month high of $1.02. The company’s market capitalization is $13.06 million. The firm’s 50 day moving average price is $0.56 and its 200-day moving average price is $0.64.

Earnings History for OXiGENE (NASDAQ:MATN)

Separately, Rodman & Renshaw began coverage on OXiGENE in a report on Monday, August 22nd. They set a “buy” rating and a $2.00 price target on the stock.

OXiGENE Company Profile

Mateon Therapeutics, Inc, formerly OXiGENE, Inc, is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT.

5 Day Chart for NASDAQ:MATN

Receive News & Stock Ratings for OXiGENE Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OXiGENE Inc. and related stocks with our FREE daily email newsletter.